抗原脱落可能提高抗体类抗癌药物在实体瘤中传递的效率。
Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors.
机构信息
Department of Chemistry and Institute of Functional Materials, Pusan National University, Busan, Republic of Korea.
出版信息
Cancer Res. 2012 Jul 1;72(13):3143-52. doi: 10.1158/0008-5472.CAN-11-3925. Epub 2012 May 4.
Abstract
Recombinant immunotoxins (RIT) are targeted anticancer agents that are composed of a targeting antibody fragment and a protein toxin fragment. SS1P is a RIT that targets mesothelin on the surface of cancer cells and is being evaluated in patients with mesothelioma. Mesothelin, like many other target antigens, is shed from the cell surface. However, whether antigen shedding positively or negatively affects the delivery of RIT remains unknown. In this study, we used experimental data with SS1P to develop a mathematical model that describes the relationship between tumor volume changes and the dose level of the administered RIT, while accounting for the potential effects of antigen shedding.
摘要
重组免疫毒素（RIT）是一种靶向抗癌药物，由靶向抗体片段和蛋白毒素片段组成。SS1P 是一种针对癌细胞表面间皮素的 RIT，正在间皮瘤患者中进行评估。间皮素与许多其他靶抗原一样，从细胞表面脱落。然而，抗原脱落是正面还是负面影响 RIT 的递送尚不清楚。在这项研究中，我们使用 SS1P 的实验数据开发了一个数学模型，该模型描述了肿瘤体积变化与给予的 RIT 剂量水平之间的关系，同时考虑了抗原脱落的潜在影响。
相似文献
1
Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors.抗原脱落可能提高抗体类抗癌药物在实体瘤中传递的效率。
Cancer Res. 2012 Jul 1;72(13):3143-52. doi: 10.1158/0008-5472.CAN-11-3925. Epub 2012 May 4.
2
Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.基于数学模型研究抗原脱落对免疫毒素在实体瘤中靶向递送的影响
PLoS One. 2014 Oct 24;9(10):e110716. doi: 10.1371/journal.pone.0110716. eCollection 2014.
3
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.表面间皮素脱落减少可提高间皮素靶向重组免疫毒素的疗效。
Mol Cancer Ther. 2016 Jul;15(7):1648-55. doi: 10.1158/1535-7163.MCT-15-0863. Epub 2016 May 18.
4
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.一种针对肿瘤相关抗原间皮素的重组免疫毒素，经过重新设计，提高了活性、降低了脱靶毒性和抗原性。
Mol Cancer Ther. 2013 Jan;12(1):48-57. doi: 10.1158/1535-7163.MCT-12-0336. Epub 2012 Nov 6.
5
Immunogenicity of therapeutic recombinant immunotoxins.治疗性重组免疫毒素的免疫原性。
Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390.
6
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.免疫毒素 SS1P 的细胞毒性活性受 TACE 依赖性间皮素脱落的调节。
Cancer Res. 2011 Sep 1;71(17):5915-22. doi: 10.1158/0008-5472.CAN-11-0466. Epub 2011 Jul 20.
7
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.免疫毒素的抗肿瘤作用通过降低 HCK 或用 SRC 激酶抑制剂治疗来增强。
Mol Cancer Ther. 2014 Jan;13(1):82-9. doi: 10.1158/1535-7163.MCT-13-0726. Epub 2013 Oct 21.
8
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.抗间皮素免疫毒素 SS1P 联合培美曲塞和顺铂一线治疗胸膜间皮瘤的 1 期研究及肿瘤缓解与血清间皮素、巨核细胞生成素和癌抗原 125 的相关性
Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2.
9
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.SS1P 免疫毒素诱导免疫原性细胞死亡标志物的产生，并增强 CTLA-4 阻断在 AE17M 小鼠间皮瘤肿瘤中的作用。
Toxins (Basel). 2018 Nov 14;10(11):470. doi: 10.3390/toxins10110470.
10
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.一种用于研究免疫毒素治疗的体外人间皮瘤 3D 模型的开发和特性描述。
PLoS One. 2011 Jan 31;6(1):e14640. doi: 10.1371/journal.pone.0014640.
引用本文的文献
1
Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin.单域抗独特型分布增强剂对曲妥珠单抗处置及PE24-曲妥珠单抗免疫毒素疗效的影响评估
Cancers (Basel). 2025 Apr 27;17(9):1468. doi: 10.3390/cancers17091468.
2
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.嵌合抗原受体（CAR）-T细胞疗法抗原依赖性耐药机制。
Cancer Cell Int. 2025 Feb 24;25(1):64. doi: 10.1186/s12935-025-03697-y.
3
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.靶抗原特性及其对血液系统恶性肿瘤和实体瘤中临床批准的抗体药物偶联物（ADC）的贡献
Cancers (Basel). 2023 Mar 19;15(6):1845. doi: 10.3390/cancers15061845.
4
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors.增强单克隆抗体在实体瘤中摄取和分布的策略。
Cancer Biol Med. 2021 Aug 15;18(3):649-64. doi: 10.20892/j.issn.2095-3941.2020.0704.
5
Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.曲妥珠单抗与肿瘤结合的瞬时抑制作用以克服“结合位障碍”并提高曲妥珠单抗-蓖麻毒素免疫毒素的疗效。
Mol Cancer Ther. 2022 Oct 7;21(10):1573-1582. doi: 10.1158/1535-7163.MCT-22-0192.
6
Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.曲妥珠单抗-HER2结合竞争性抑制剂的开发与评估以绕过结合位点障碍
Front Pharmacol. 2022 Feb 18;13:837744. doi: 10.3389/fphar.2022.837744. eCollection 2022.
7
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond.抗体药物偶联物：作用原理及其在肿瘤学及其他领域的应用
Vaccines (Basel). 2021 Sep 29;9(10):1111. doi: 10.3390/vaccines9101111.
8
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.嵌合抗原受体 T 细胞靶向间皮素治疗急性髓系白血病。
Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11.
9
Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy.瞬时竞争性抑制绕过结合位点障碍，提高曲妥珠单抗的肿瘤穿透性并增强 T-DM1 的疗效。
Cancer Res. 2021 Aug 1;81(15):4145-4154. doi: 10.1158/0008-5472.CAN-20-3822. Epub 2021 Mar 16.
10
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.针对实体瘤的间皮素靶向重组免疫毒素。
Biomolecules. 2020 Jun 28;10(7):973. doi: 10.3390/biom10070973.
本文引用的文献
1
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.一种通过添加二硫键来提高稳定性的重组免疫毒素，其免疫原性降低。
Protein Eng Des Sel. 2012 Jan;25(1):1-6. doi: 10.1093/protein/gzr053. Epub 2011 Nov 17.
2
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.免疫毒素 SS1P 的细胞毒性活性受 TACE 依赖性间皮素脱落的调节。
Cancer Res. 2011 Sep 1;71(17):5915-22. doi: 10.1158/0008-5472.CAN-11-0466. Epub 2011 Jul 20.
3
Investigational antibody drug conjugates for solid tumors.用于实体瘤的研究性抗体药物偶联物。
Expert Opin Investig Drugs. 2011 Aug;20(8):1131-49. doi: 10.1517/13543784.2011.582866. Epub 2011 May 23.
4
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.纳米药物向实体瘤细胞外和细胞内区室的递送。
Adv Drug Deliv Rev. 2012 Jan;64(1):29-39. doi: 10.1016/j.addr.2011.04.006. Epub 2011 May 3.
5
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.ABT-737 克服了免疫毒素介导的细胞凋亡抗性，并增强了基于铜绿假单胞菌外毒素的蛋白向细胞质的递送。
Mol Cancer Ther. 2010 Jul;9(7):2007-15. doi: 10.1158/1535-7163.MCT-10-0257. Epub 2010 Jun 29.
6
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.一种流式细胞术方法可定量分析内化的免疫毒素，结果表明紫杉醇协同增加了细胞内免疫毒素的摄取。
Cancer Res. 2010 Feb 1;70(3):1082-9. doi: 10.1158/0008-5472.CAN-09-2405. Epub 2010 Jan 26.
7
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.持续输注抗间皮素重组免疫毒素SS1P的I期试验。
Clin Cancer Res. 2009 Aug 15;15(16):5274-9. doi: 10.1158/1078-0432.CCR-09-0062. Epub 2009 Aug 11.
8
Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way.在小鼠中，白皂角苷以协同方式显著增强了靶向毒素对肿瘤生长的抑制作用。
J Immunother. 2009 Sep;32(7):713-25. doi: 10.1097/CJI.0b013e3181ad4052.
9
High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.肿瘤内高脱落抗原水平：免疫偶联疗法的又一障碍。
Clin Cancer Res. 2008 Dec 15;14(24):7981-6. doi: 10.1158/1078-0432.CCR-08-0324.
10
Developments in macromolecular drug delivery.大分子药物递送的进展。
Methods Mol Biol. 2009;480:1-10. doi: 10.1007/978-1-59745-429-2_1.
Zotero 插件